like trying to empty the ocean with a spoon
En las selvas y ciudades empobrecidas de la República Democrática del Congo, un brote de ébola causado por una variante poco conocida y sin tratamiento eficaz acumula más de 750 casos sospechosos y 170 muertes, cifras que los expertos consideran apenas la superficie de una crisis más profunda. José Luis del Pozo, especialista en enfermedades infecciosas con experiencia directa en la región, advierte que este podría ser el brote más grave desde que el virus fue identificado en 1976. La humanidad se enfrenta, una vez más, a la pregunta de si actuará con la urgencia que exige lo que aún no puede ver ni medir.
- Una variante del ébola sin vacuna ni tratamiento probado se propaga en el Congo a una velocidad mayor de lo que los epidemiólogos anticipaban, encendiendo las alarmas de la comunidad sanitaria internacional.
- Las cifras oficiales —más de 750 casos y 170 muertos— probablemente subestiman la magnitud real del brote, ya que los síntomas del ébola se confunden fácilmente con malaria y fiebre tifoidea en regiones sin capacidad diagnóstica suficiente.
- Contener el virus en zonas con escasez crónica de personal médico, equipos y suministros básicos es, según del Pozo, como intentar vaciar el océano con una cuchara.
- El rastreo de contactos —herramienta esencial para frenar la transmisión— se vuelve casi imposible en territorios donde ni siquiera se conoce con certeza la población a proteger.
- La crisis abre, sin embargo, una ventana: la presión internacional podría acelerar el desarrollo de tratamientos y vacunas específicos para esta variante, si los países con recursos deciden actuar antes de que la amenaza llegue a sus fronteras.
José Luis del Pozo lleva años estudiando enfermedades infecciosas en algunos de los sistemas sanitarios más frágiles del mundo. Como jefe de enfermedades infecciosas y microbiología en la Clínica Universidad de Navarra, ha trabajado sobre el terreno en Congo y Uganda. Lo que observa ahora le preocupa profundamente.
La Organización Mundial de la Salud registra más de 750 casos sospechosos y al menos 170 muertes por un brote de ébola en la República Democrática del Congo. Pero lo que inquieta especialmente a del Pozo no son solo las cifras: es la variante en cuestión, una cepa distinta de las formas más conocidas del virus, para la que no existe vacuna eficaz ni tratamiento probado, y que parece transmitirse entre personas con mayor facilidad que en brotes anteriores.
Del Pozo califica este episodio como potencialmente uno de los más graves desde que el virus fue identificado en 1976. Las cifras oficiales, advierte, casi con certeza subestiman la realidad: los síntomas del ébola —fiebre, debilidad, dolor muscular— son casi idénticos a los de la malaria y la fiebre tifoidea, enfermedades mucho más comunes en la región. Sin capacidad diagnóstica sofisticada, los casos se confunden y no se contabilizan.
Los desafíos logísticos son enormes. Contener un brote en estas condiciones es, según sus palabras, como intentar vaciar el océano con una cuchara: faltan médicos, equipos y suministros básicos, y en muchas zonas las autoridades sanitarias ni siquiera conocen la población real que deben proteger. El rastreo de contactos, herramienta fundamental para cortar la transmisión, se vuelve casi inviable.
Sin embargo, del Pozo identifica una posible consecuencia positiva: esta crisis debería impulsar la inversión en nuevos tratamientos y vacunas específicos para esta variante. La investigación farmacéutica suele acelerarse solo cuando un brote amenaza a los países ricos. La pregunta es si la comunidad internacional actuará con la urgencia que la situación exige, antes de que el virus avance más allá de lo que las cifras actuales —incompletas y probablemente optimistas— logran reflejar.
José Luis del Pozo has spent years studying infectious disease in some of the world's most fragile health systems. As head of infectious diseases and microbiology at the University of Navarra Clinic in Spain, he has worked on the ground in Congo and Uganda, watching outbreaks unfold in places where basic resources are scarce. What he sees unfolding now in the Democratic Republic of Congo troubles him deeply.
The World Health Organization is tracking an Ebola outbreak that has already produced more than 750 suspected cases and claimed at least 170 lives. The numbers alone would be alarming. But what makes del Pozo genuinely concerned is the variant itself—a strain distinct from the more familiar forms of the virus, one for which there is currently no effective vaccine and no proven treatment. The outbreak is also spreading faster than epidemiologists expected, and the virus appears to be transmitting between people more readily than it has in previous outbreaks.
Del Pozo calls this potentially one of the most significant Ebola crises since 1976, when the virus was first identified. He speaks carefully but without hedging: the outbreak could be "the tip of the iceberg." The official case counts, he explains, almost certainly underestimate what is actually happening on the ground. Ebola's symptoms—fever, weakness, muscle pain—look almost identical to malaria and typhoid fever, diseases far more common in the region. Without sophisticated diagnostic capacity, which the Democratic Republic of Congo lacks, cases go misidentified and uncounted. The true scale of the outbreak may be substantially larger than reported figures suggest.
The logistical and medical challenges are staggering. Del Pozo describes the effort to contain an outbreak in these regions as "like trying to empty the ocean with a spoon." The Democratic Republic of Congo faces chronic shortages of medical staff, equipment, and basic supplies. In many areas, health authorities don't even know the actual population they're trying to protect. Contact tracing—the fundamental tool for stopping transmission—becomes nearly impossible when you cannot reliably locate or count the people in your jurisdiction.
Yet del Pozo sees a potential opening. He argues that this crisis, as devastating as it is, should catalyze investment in new treatments and vaccines specifically designed for this variant. Research funding and pharmaceutical development typically accelerate only when an outbreak feels immediate and threatening to wealthy nations. This outbreak, spreading in a region with limited resources to contain it, represents exactly the kind of threat that should trigger that response. "Hopefully," he says, "this will at least drive the development of some effective drug or vaccine for this particular type of Ebola virus."
The question now is whether the international health community will act with the urgency the situation demands. Del Pozo's warning is not speculative—it is grounded in direct experience of how these outbreaks behave in under-resourced settings. The numbers we see are likely incomplete. The virus is moving faster than expected. And the tools to stop it do not yet exist.
Notable Quotes
This could be one of the most significant Ebola outbreaks since 1976— José Luis del Pozo, infectious disease specialist
Hopefully this will drive the development of some effective drug or vaccine for this particular type of Ebola virus— José Luis del Pozo
The Hearth Conversation Another angle on the story
When you say the official numbers are probably just the tip of the iceberg, how much larger do you think the real outbreak might be?
That's the difficult part—we can't know precisely. But when you have malaria and typhoid circulating in the same areas, and Ebola produces similar early symptoms, many cases simply get misdiagnosed. People die at home, in villages without access to testing. The true number could be two, three, even five times higher than what's reported.
You've worked in these regions. What's the single biggest obstacle to containing this?
Resources, but not just money. It's the absence of everything at once—trained epidemiologists, functioning laboratories, reliable transportation, communication networks. You can't trace contacts if you don't know where people live. You can't test samples if you have no equipment.
This variant has no vaccine. How does that change the calculus of what's possible?
It changes everything. With previous outbreaks, we at least had tools, even if imperfect ones. Here, we're essentially defenseless. That's why this outbreak should be a wake-up call for research investment. We need to develop countermeasures now, not after thousands more die.
Do you think the international response will be adequate?
History suggests no. We only invest heavily in research when we feel directly threatened. Congo is distant, poor, and doesn't command the same attention as an outbreak in a wealthy nation would. That's the bitter reality.